MX9606055A - Formulation of topic use of acetic acid more blue than methylene, for the treatment of local skin and mucous infections caused by virus. - Google Patents

Formulation of topic use of acetic acid more blue than methylene, for the treatment of local skin and mucous infections caused by virus.

Info

Publication number
MX9606055A
MX9606055A MX9606055A MX9606055A MX9606055A MX 9606055 A MX9606055 A MX 9606055A MX 9606055 A MX9606055 A MX 9606055A MX 9606055 A MX9606055 A MX 9606055A MX 9606055 A MX9606055 A MX 9606055A
Authority
MX
Mexico
Prior art keywords
formulation
blue
acetic acid
methylene
virus
Prior art date
Application number
MX9606055A
Other languages
Spanish (es)
Other versions
MXPA96006055A (en
Inventor
Alvaro Emmanuel Conzue Quijada
Original Assignee
Alvaro Emmanuel Conzue Quijada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alvaro Emmanuel Conzue Quijada filed Critical Alvaro Emmanuel Conzue Quijada
Priority to MXPA/A/1996/006055A priority Critical patent/MXPA96006055A/en
Priority claimed from MXPA/A/1996/006055A external-priority patent/MXPA96006055A/en
Publication of MX9606055A publication Critical patent/MX9606055A/en
Publication of MXPA96006055A publication Critical patent/MXPA96006055A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The formulation of 99.8 percent acetic acid more blue to 1 percent methylene is useful and efficient for the topic application of viral infections located in the skin and mucous. This utility is derived from the capacity of the formulation to inactivate local virus and denaturalize proteins in contact with the epithelium, causing superficial destruction of infected cells. The adequate and prudent use of the formulation can be applied in vivo in affected patients and benefit thousands of persons.
MXPA/A/1996/006055A 1996-12-03 Formulation of topical use of acetic acid and blue methylene, for treatment of local skin and mucous infections caused by vi MXPA96006055A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MXPA/A/1996/006055A MXPA96006055A (en) 1996-12-03 Formulation of topical use of acetic acid and blue methylene, for treatment of local skin and mucous infections caused by vi

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXPA/A/1996/006055A MXPA96006055A (en) 1996-12-03 Formulation of topical use of acetic acid and blue methylene, for treatment of local skin and mucous infections caused by vi

Publications (2)

Publication Number Publication Date
MX9606055A true MX9606055A (en) 1998-06-30
MXPA96006055A MXPA96006055A (en) 1998-10-30

Family

ID=

Similar Documents

Publication Publication Date Title
PT932411E (en) COMPOSITIONS CONTAINING IMMUNOGENIC MOLECULES AND STIMULATING FACTOR OF MACROFAGUES COLONIES- GRANULOCYTS AS ADJUVANT
NO20026044L (en) Treatment of human papillomavirus
BR9814606A (en) Vaccine formulation and methods of treating an individual infected with an hpv virus and preventing papillomavirus infection
DE59509624D1 (en) APPLICATION OF SOD IN LIPOSOMES
AU1346283A (en) Sterilised plasma and plasma derivatives
ATE183087T1 (en) USE OF BETA-HYDROXY-BETA-METHYLBUTYRATE ACID TO PROMOTE NITROGEN RETENTION IN HUMANS
ID27502A (en) 3-6 (AMINO-OR AMINOALKIL) PYRIDINONS AND ITS USE FOR TREATMENT OF HIV-RELATED DISEASES
BR9910251A (en) Hematopoietic stimulation
AU1830692A (en) A blood product, a method of producing the same and a method of determining the virus inactivation capacity of an inactivation treatment
TR199701490A2 (en) 3-Hydroxypyridine-2-carbon acidamidester and their manufacture.
ES2151607T3 (en) GROWTH AND DIFFERENTIATION FACTOR 12.
TR200002248T2 (en) New dihydroxyhexanoic acid derivatives
AU2001261986A1 (en) Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
KR930702019A (en) Skin, corneal disease treatment
EP1093816A3 (en) Use of ST1435 in hormonal therapy by transdermal application
MX9606055A (en) Formulation of topic use of acetic acid more blue than methylene, for the treatment of local skin and mucous infections caused by virus.
MY106036A (en) Preventing agent for human immunodeficiency virus infection comprising menfegol.
DE69733539D1 (en) TOPICAL AGENTS CONTAINING AN AMINO ACID IN COMBINATION WITH EITHER INTERFERON OR WITH THYMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR INFLAMMATORY DISEASES
Li et al. Analysis of 155 patients with chemical injury: a 5-year experience
CA2294950A1 (en) Levobupivacaine and its use
EP1240899A3 (en) Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
AU8759298A (en) Use of nordihydroguaiaretic acid to lower serum triglycerides, blood pressure and to treat syndrome
NO20024381L (en) Preparation for use in the treatment of ocular hypertension and glaucoma
GR930300031T1 (en) Method and composition for the treatment of mammalian hiv infection.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees